Cancer Family
Malignant Nervous System Neoplasm
CI-CAN-00000246Explore in graph →
954 active trials7 approved drugs131 evidence items
- NCIt
- C4788
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000246Explore in graph →
Clinical trials
3,459 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (494)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01473901 | A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 | 38 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 9, 2020 | clinicaltrials |
| NCT01934361 | Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 | 35 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 9, 2020 | clinicaltrials |
| NCT03603379 | Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas(GBM-LIPO) | completed | Phase 1 | 9 | University Hospital, Basel, SwitzerlandOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT03880123 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | withdrawn | Phase 1 | 0 | Matthew InghamOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT00031083 | Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas | completed | Phase 1 | 12 | BiogenINDUSTRY | 1 | Nov 17, 2020 | clinicaltrials |
| NCT03619239 | Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma(GBM) | completed | Phase 1 | 15 | Genexine, Inc.INDUSTRY | 1 | Nov 10, 2020 | clinicaltrials |
| NCT02607124 | A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy | terminated | Phase 1 / Phase 2 | 11 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT00052208 | Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 158 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT01704872 | ch14.18/CHO Bridging Study | completed | Phase 1 | 16 | St. Anna KinderkrebsforschungOTHER | 3 | Oct 22, 2020 | clinicaltrials |
| NCT04270461 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | withdrawn | Phase 1 | 0 | Jiujiang University Affiliated HospitalOTHER_GOV | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03463733 | Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)(HUTMZ) | unknown | Phase 1 | 54 | M.E. van LindeOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT00050986 | Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 55 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 22, 2020 | clinicaltrials |
| NCT01916187 | Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma | withdrawn | Phase 1 | 0 | NCIC Clinical Trials GroupNETWORK | 1 | Sep 21, 2020 | clinicaltrials |
| NCT04547621 | HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM(HSCK-010) | unknown | Phase 1 / Phase 2 | 50 | Huashan HospitalOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT02590263 | Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma | completed | Phase 1 / Phase 2 | 53 | AbbVieINDUSTRY | 1 | Sep 3, 2020 | clinicaltrials |
| NCT02271711 | Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors | completed | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT00402116 | Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients | completed | Phase 1 / Phase 2 | 72 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 6, 2020 | clinicaltrials |
| NCT03734913 | A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 65 | Guangdong Zhongsheng Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
| NCT01701479 | Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)(LTI) | unknown | Phase 1 / Phase 2 | 288 | St. Anna KinderkrebsforschungOTHER | 7 | Jul 14, 2020 | clinicaltrials |
| NCT03707457 | Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma | terminated | Phase 1 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 2, 2020 | clinicaltrials |
| NCT01790503 | A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 65 | Daiichi SankyoINDUSTRY | 1 | Jun 30, 2020 | clinicaltrials |
| NCT01349660 | Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 88 | SCRI Development Innovations, LLCOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT03231501 | HMPL-813 in Treating Patients With Glioblastoma | unknown | Phase 1 | 29 | Hutchison Medipharma LimitedINDUSTRY | 1 | Jun 16, 2020 | clinicaltrials |
| NCT00939770 | Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | completed | Phase 1 / Phase 2 | 122 | Children's Oncology GroupNETWORK | 2 | Jun 9, 2020 | clinicaltrials |
| NCT04388033 | Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients. | unknown | Phase 1 / Phase 2 | 10 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 9, 2020 | clinicaltrials |
| NCT04120350 | R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty(REMLA) | unknown | Phase 1 / Phase 2 | 47 | Peking Union Medical College HospitalOTHER | 1 | Jun 5, 2020 | clinicaltrials |
| NCT02502708 | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | completed | Phase 1 | 81 | NewLink Genetics CorporationINDUSTRY | 1 | Jun 4, 2020 | clinicaltrials |
| NCT01331135 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors(Aflac ST0901) | completed | Phase 1 | 18 | Emory UniversityOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT01260506 | Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 75 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 2 | Apr 24, 2020 | clinicaltrials |
| NCT02116959 | Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma | terminated | Phase 1 | 6 | University of California, San FranciscoOTHER | 1 | Apr 16, 2020 | clinicaltrials |
| NCT02390843 | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors(AflacST1402) | completed | Phase 1 | 13 | Emory UniversityOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT01614132 | Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults(NOA-07) | completed | Phase 1 / Phase 2 | 33 | University of RegensburgOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT02855086 | Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery | terminated | Phase 1 / Phase 2 | 3 | Eben RosenthalOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT04327011 | A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511 | terminated | Phase 1 | 65 | Tocagen Inc.INDUSTRY | 1 | Mar 30, 2020 | clinicaltrials |
| NCT02529072 | Nivolumab With DC Vaccines for Recurrent Brain Tumors(AVERT) | completed | Phase 1 | 6 | Gary Archer Ph.D.OTHER | 1 | Mar 26, 2020 | clinicaltrials |
| NCT01400672 | Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma | terminated | Phase 1 | 8 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT00062881 | Intrathecal Mafosfamide | completed | Phase 1 | 65 | Baylor College of MedicineOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT02792036 | Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma | completed | Phase 1 | 8 | St. Jude Children's Research HospitalOTHER | 1 | Feb 20, 2020 | clinicaltrials |
| NCT00007813 | Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors | completed | Phase 1 | 21 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT03573986 | Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment | terminated | Phase 1 | 2 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT03973879 | Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma | withdrawn | Phase 1 / Phase 2 | 0 | Darell BignerOTHER | 0 | Feb 11, 2020 | clinicaltrials |
| NCT02764151 | First in Patient Study for PF-06840003 in Malignant Gliomas | terminated | Phase 1 | 17 | PfizerINDUSTRY | 1 | Jan 27, 2020 | clinicaltrials |
| NCT02378532 | The Addition of Chloroquine to Chemoradiation for Glioblastoma(CHLOROBRAIN) | completed | Phase 1 | 13 | Maastricht Radiation OncologyOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT01222780 | To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer | completed | Phase 1 | 22 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 18, 2020 | clinicaltrials |
| NCT00390299 | Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 | 23 | Mayo ClinicOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT01962103 | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 107 | CelgeneINDUSTRY | 7 | Dec 27, 2019 | clinicaltrials |
| NCT03507244 | Concurrent Intrathecal-pemetrexed and Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumors | completed | Phase 1 / Phase 2 | 34 | The First Hospital of Jilin UniversityOTHER | 1 | Dec 26, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Dec 9, 2020source: clinicaltrials